SCHEMBL25447709

SCHEMBL25447709

CCNC(=O)c1c(OC)cnn1CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.40
TSHR P16473 3/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PDE10A Q9Y233 1/20 0.38
NPC1 O15118 1/20 0.38
ATM Q13315 1/20 0.38
HPGD P15428 1/20 0.38
BLM P54132 1/20 0.38
PRKAB2 O43741 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23135542 0.84 LMNA (0.45) LMNAKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL7523606 0.78 POLB (0.42) LMNAKDM4EALDH1A1POLBTSHR
SCHEMBL21281700 0.68 HTT (0.44) LMNAKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL31332838 0.67 KMT2A (0.58) LMNAKDM4EALDH1A1MAPTPOLB
SCHEMBL569285 0.67 KDM4E (0.43) KDM4EALDH1A1MAPTPOLBTSHR
SCHEMBL21621336 0.66 LMNA (0.43) LMNAKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL7510168 0.65 PDE10A (0.43) LMNAKDM4EALDH1A1POLBTSHR
SCHEMBL7515644 0.65 KMT2A (0.58) LMNAALDH1A1MAPTL3MBTL1POLB
SCHEMBL29899310 0.65 ALDH1A1 (0.51) LMNAKDM4EALDH1A1MAPTKMT2A
SCHEMBL12826268 0.65 GAA (0.40) KDM4EALDH1A1MAPTL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230141212-A1 SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS DICE ALPHA, INC. 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141212-A1 SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS IL17A, IL2, IL23R LMNA 3731/4885KDM4E 613/4885ALDH1A1 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.